New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sabinsa Granted Forskolin Process Patent For New Zealand

Sabinsa has received a Grant of Patent from the New Zealand Patent Office, which describes processes to prepare derivatives of forskolin, namely, isoforskolin and 7-deacetylforskolin.

NZ Patent No: 568652 “Commercial Process for Making Forskolin and its Derivatives” will be in force until February 2, 2027.

This most recent patent is #63 in Sabinsa’s sizeable worldwide Intellectual Property portfolio. Additionally, Sabinsa has over 50 pending patent applications worldwide. The company continues to demonstrate its commitment to keeping the spirit of innovation alive in the industry, through sustained intellectual property creation and protection efforts.

This patent furthers Sabinsa’s ability to protect their Intellectual Property as they make inroads into Oceania. The company recently received Product Information (PI) numbers for ForsLean® 10% and 20% from Australia’s TGA (Therapeutic Goods Administration), a division of the Australian Government Department of Health and Ageing, opening the way for ForsLean to enter the Australian market.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.